Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

June 5, 2023

NMPA grants BTD to Innovent’s olverembatinib to treat SDH-deficient GIST

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to Innovent Biologics’ olverembatinib for the treatment of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST).

NMPA grants BTD to Innovent’s olverembatinib to treat SDH-deficient GIST